Although T cells are the main targets of inhibition, the PD pathway may also impair the anti-tumor function of innate immune cells through a PD-L1/PD-1 counter-receptor interaction, including DCs, macrophages, and NK cells. Here, PDCD1 is linked to neoplasm.